Extensive-stage small-cell lung cancer: new approaches on the horizon?
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
Mixed outcomes with novel targeted therapies for HER2-positive upper GI cancers
While a HER2-targeted bispecific antibody showed extended survival in pre-treated gastric cancers, TKI–immunotherapy combinations failed to confer a survival benefit
Long-term phase III data reinforce the benefits of CDK4/6 inhibitors in early breast cancer
Follow-up data at 7 and 5 years from monarchE and NATALEE provide reassurance of the sustained benefits of adjuvant CDK4/6 inhibitors in improving survival and reducing relapse
Optimising cancer care for individual patients is key to improving outcomes for all
An ESMO roadmap addresses how the new challenges in oncology can be transformed into opportunities for the benefits of oncology professionals and patients with cancer
Personalising cancer treatment with AI and digital pathology
Leveraging artificial intelligence and digital pathology, oncology is entering a transformative stage where advanced image analysis and AI-driven biomarkers enable personalised cancer treatment decisions.
Status and trends in digital pathology
Pathology is going digital. More than 50 AIs cleared for diagnostic use are now available. This article summarises the status quo and gives an outlook of upcoming emerging technologies.
Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use
Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma
In a phase III trial, lower doses of adjuvant radiotherapy plus docetaxel were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy, with an impact on quality of life
Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions